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1. ABSTRACT 
1.1 Abstract 
Most human malignant tumours are carcinomas, and the most common cause of mortality is 
due to metastasis. The E3 ubiquitin-ligase Hakai protein is responsible of the degradation of the 
E-cadherin at post-traslational level, and in consequence the activation of the epithelial-to-
mesenchymal transition programme (EMT). In this study, I analysed the expression levels of 
the heat shock proteins Hsp70 and Hsp90, previously identified as Hakai-regulated proteins and 
notoriously related to cancer. I analysed the expression of these proteins in healthy colon 
tissues, adenoma and different TNM-tumour stages. Then, the expression levels of Hsp90 were 
analysed by transiently overexpressing Hakai in colon epithelial tumour cells. The Hsp90 levels 
increase in the transition from healthy and adenoma to carcinoma in human colon 
adenocarcinoma progression. Furthermore, by immunofluorescence it was detected an increase 
Hsp90 protein expression in Hakai-transfected LoVo cells. 
 
1.2 Resumen 
La mayoría de los tumores malignos humanos son carcinomas y la mayoría de las muertes por 
cáncer son debidas a las metástasis. La proteína E3 ubiquitin-ligasa Hakai es responsable de la 
degradación de E-cadherina a nivel postraduccional, y en consecuencia se activa el programa 
de  transición epitelio-mesénquima (EMT). En este estudio, analicé los niveles de expresión de 
las proteínas de choque térmico Hsp70 y Hsp90, previamente identificadas como proteínas 
reguladas por Hakai y con un papel relevante en cáncer. Analicé la expresión de estas proteínas 
en tejidos de colon sanos, adenomas y diferentes estadios TNM de progresión tumoral.  A 
continuación, los niveles de expresión de Hsp90 fueron analizados tras la sobreexpresion 
transitoria de Hakai en células epiteliales tumorales de colon. Mis resultados indican que los 
niveles de Hsp90 se incrementan en la transición de tejidos sanos y adenoma a carcinoma en la 
progresión tumoral de adenocarcinoma humano. Además, por immunofluorescencia detecté un 
incremento en los niveles de expresión de proteína Hsp90 en las células LoVo transfectadas 
con Hakai. 
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1.3 Resumo 
A maioría dos tumores malignos en humanos son carcinomas e a maioría das mortes por cancro 
son debidas á metástase. A proteína E3 ubiquitín-ligasa Hakai é responsable da degradación de 
E-cadherina a nivel postraduccional, e en consecuencia actívase o programa de transición 
epitelio-mesénquima (EMT). Neste estudo, analicei os niveis de expresión das proteínas de 
choque térmico Hsp70 e Hsp90, previamente identificadas como proteínas reguladas por Hakai 
e con un papel relevante no cancro. Analicei a expresión destas proteínas en tecidos de colon 
sans, adenomas e diferentes estadios TNM de progresión tumoral. A continuación, os niveis de 
expresión de Hsp90 foron analizados tra a sobreexpresión transitoria de Hakai en células 
epiteliais tumorais de colon. Os meus resultados indican que os niveis de Hsp90 increméntanse 
na transición de texidos sanos e adenoma a carcinoma na progresión tumoral de 
adenocarcinoma humano. Ademais, por inmunofluorescencia detectei un incremento dos niveis 
de expresión da proteína Hsp90 nas células LoVo transfectadas con Hakai. 
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2. INTRODUCTION 
Cancer is one of the main causes of morbidity and mortality worldwide. The phenomenon that 
gives rise to the formation and development of cancer is called carcinogenesis. Through 
carcinogenesis, healthy cells are transformed into cancer cells by genotypic and phenotypic 
changes. Carcinogenesis is characterized by a series of genetic and cellular modifications that 
lead the cell to divide in an uncontrolled way. Malignant tumour formation requires the 
conversion of a benign hyperplasia (condition that results in an increase of the number of cells) 
to a malignant state (Kufe et al, 2003). In most cases, genetic alterations involve activation of 
oncogenes and/or deactivation of tumour suppressor genes leading to uncontrolled cell cycle 
progression and inactivation of apoptotic mechanism (Sarkar et al, 2013). A malignant tumour, 
however, is capable of both invading surrounding normal tissue and spreading throughout the 
body via the circulatory or lymphatic systems, these features, respectively called, “invasion” 
and “metastasis” are manifestations of further genetic and epigenetic changes. Only malignant 
tumours are properly referred to as cancers, and are characterized by their ability to invade and 
metastasize in a distant organ (Cooper., 2000).  
 
 
Figure 1. Schematic representation of the 
basic differences between a benign 
tumour and a malignant tumour (cancer). 
(Source: National Cancer Institute) 
 
 
 
 
 Most human malignant tumours are carcinomas and almost 90% of cancer-associated 
mortality is due to metastasis. Carcinomas arise from the epithelial cells transformation 
(Hanahan et al, 2000). The canonical mechanisms involved in generation of carcinomas are 
mutation, chromosomal translocation or deletion, and dysregulated expression or activity of 
signalling pathways. These events may activate genes that promote deregulated cell cycling 
and/or inactivate apoptotic pathways (Fearon et al,1990; Vogelstein et al, 2004). The 
development and progression of cancer are part of a multistep process in which growth control 
is increasingly impaired. The presence of several genetic alterations in cancer cells strongly 
indicated that those alterations accumulate in the cells in a stepwise manner during tumour 
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progression (Yokota, 2000). Cancer is the outcome of an evolutionary process involving 
successive generations of cells, which are progressively further advanced towards cancerous 
growth (Yoshida et al, 2000). 
During tumour progression continuously additional mutations occur within cells of the tumour 
population resulting in an increased amounts of particular proteins in the malignant cells. This 
process allows to tumour cells to evolved on the basis of its increased growth rate or other 
properties (survival, invasion and metastasis) that confer a selective advantage. This 
phenomenon, called “clonal selection”, continues throughout cancer development so tumours 
continuously become more rapid-growing and increasingly malignant (Nowell, 1986). 
Malignant carcinomas may arise from the benign adenomas, when tumour cells start to invade 
through the basal lamina into underlying connective tissue occurs. Then, cancer cells then 
continue to proliferate and spread through the connective tissues. Eventually the cancer cells 
penetrate the wall of neighbouring organs and invade blood and lymphatic vessels to finally 
metastasize throughout the body. Important number of studies have provided clear evidence 
that specific stages in malignant transformation can occur discretely (Stracke et al, 1992). 
 
 
2.1 Epithelial-to-mesenchymal transition during tumour progression 
A feature that allows benign tumours to become malignant tumours is acquisition of the 
invasive characteristics. In fact, a benign tumour tends to expand by compressing the 
surrounding tissues while malignant tumours tend to expand by infiltrating them. The term 
“invasion” refers to the direct extension and penetration of cancer cells into neighbouring 
tissues. The infiltration process requires the active ability to penetrate through the tissues, with 
the degradation of the extracellular matrix and the disruption of the organ's architecture, 
including disruption of cell-cell contacts and cell-substratum adhesions (Brabletz et al, 2018). 
Metastasis are malignant cells that break away from the original tumour and spread to distant 
organs where they can reproduce and generate new tumours. Metastatic process is defined as 
“dissemination of cancer cells from their origin to a distant organ” (Lugassy et al, 1997). 
Massive metastatic lesions lead to the development of severe organ failure and, therefore, a 
patient’s death (Tracey et al, 2013). However, at the early stage of primary tumour progression, 
the cells are not invasive and metastatic. Then, new clones with invasiveness and metastatic 
capability appear as a result of further accumulation of genetic alterations in the cells (Yokota, 
2000). 
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 During the transition from adenoma to carcinoma, cells may acquire several 
characteristic phenotypes, including enhanced cell motility and invasion, and altered cell– cell 
and cell–substratum adhesions (Figueroa et al, 2009). Through a process named epithelial-to-
mesenchymal transition (EMT), epithelial cells lose their cell–cell contacts, cell–substratum 
adhesions and apical–basal polarity, accompanied by the reorganization of the cytoskeleton and 
acquisition of a migratory or mesenchymal phenotype (Yang et al, 2008). A number of distinct 
molecular processes are engaged in order to initiate an EMT. These include activation of 
transcription factors, expression of specific cell-surface proteins, reorganization and expression 
of cytoskeletal proteins, production of extracellular matrix degradation enzymes, and changes 
in the expression of specific microRNAs (Weinberg et al, 2009). EMT is a highly controlled 
program that was firstly reported during embryogenesis (EMT type I), and also during wound 
healing and tissue repair (EMT type II). Apart from these two last mentioned physiological 
EMT, this program can also occur during pathological conditions such as tumour progression 
(EMT type III) (Aparicio et al, 2012). 
 The best characterized protein and hallmark of the EMT process is the loss of E-
cadherin. E-cadherin (epithelial cadherin) is a crucial transmembrane protein important 
to maintain stable cell-cell contacts in epithelial cells. It is well know that the loss of E-cadherin 
protein is associated with the disruption of cell-cell contacts and can promote invasive and 
metastatic behaviour in many epithelial tumours (Birchmeier et al, 1994).  
 
Figure 2. Epithelial mesenchymal 
transition (EMT) and basic 
features. During the EMT, cells lose 
cell polarity, cell adhesion and acquire 
migratory and invasion capabilities, 
accompanied by the loss of E-
cadherin protein expression. (Source: 
The Hallmarks of Cancer 6: Tissue 
Invasion and Metastasis, Buddhini S.) 
 
E-cadherin expression may be controlled at different levels of regulation. The first post-
translational regulator reported of the E-cadherin protein stability is Hakai. Hakai is an E3 
ubiquitin-ligase that binds to E-cadherin cytoplasmic domain in a phosphorylation-dependent 
manner and induce its internalization and subsequent degradation which in consequence it is 
produce the alteration of cell-cell contacts (Fujita et al, 2002). 
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2.1.1 Role of Hakai  
In 2002, Fujita et al identified a protein interacting with tyrosine phosphorylated E-cadherin by 
a modified yeast 2-hybrid screen. This protein was named Hakai, “destruction” in Japanese 
(Fujita et al, 2002). Hakai protein is encoded by CBLL1 gene and is composed by 491 
aminoacids. It is an E3 ubiquitin-ligase that can bind to a tyrosine-phosphorylated E-cadherins 
to mediate the internalization and subsequent ubiquitin-dependent substrate degradation (Pece 
et al, 2002). In the ubiquitination pathway three types of enzyme are involved: the ubiquitin-
activating enzyme (E1), ubiquitin-conjugating enzymes (E2) and a variety of ubiquitin-ligases 
(E3). These E3 ubiquitin-ligases (E3) are responsible for the specificity of the interaction with 
the target protein to degrade. Tyrosine phosphorylation of the E-cadherin complex by v-Src 
kinase (phosphoprotein involved in the initiation and the maintenance of neoplastic 
transformation) is necessary for the binding of the SH2 domain of Hakai. The Src kinase family 
have a crucial role in the regulation of many biological functions associated with cellular 
morphology changes, cellular plasticity and modulation of the intercellular adhesion during 
EMT. 
 
Figure 3. E-cadherin degradation by Hakai. 
(1) After tyrosine phosphorylation by Src of the 
cytoplasmic domain of E-cadherin, (2) Hakai 
induces the ubiquitination of E-cadherin, (3) 
following endocytosis into vesicles through the 
action of Rab5 and Rab7 (GTPases involved 
in intracellular vesicle trafficking) (4) and 
finally degrade into lysosomes which in 
consequence it is altered the integrity of cell–
cell contacts. (Modified image from source: 
Biological influence of Hakai in cancer: a 10-
year review. Aparicio et al, 2012) 
 
 
 The tyrosine residues, by wich the phosphorylation is mediated by Hakai, are only 
present in E-cadherin and not in N- or OB-cadherin, other members of cadherin family (Fujita 
et al., 2002). Therefore, it is clear the specific role of Hakai on E-cadherin proteins in epithelial 
cells. By northern blot analysis it is revealed that Hakai is ubiquitously expressed in tissues, 
included in tissues such as spleen and skeletal muscle, where E-cadherin is absent, suggesting 
that Hakai may have different substrate or different functions (Figueroa et al, 2009). The E3 
ubiquitin-ligase Hakai possesses a pTyr-binding (HYB) domain consists of a homodimer where 
each monomer consists of two zinc-finger domains: a RING domain and a minimum pTyr-
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binding domain that incorporates an atypical zinc coordination motif, on which both domain 
play key roles in the dimerization (Mukherjee et al, 2012). Therefore Hakai is active in a 
dimeric form, since its dimerization allows the formation of a phosphotyrosine-binding pocket 
that recognizes specific phosphorylated tyrosines and flanking acidic amino acids of Src 
substrates, such as E-cadherin, Cortactin or DOK1 (Mukherjee et al, 2012). 
Our group has recently published how protein expression is altered during epithelial-to-
mesenchymal transition in a Hakai-dependent manner (Diaz-Diaz et al, 2017). By proteomic 
analysis using a gel-free approach and employing isobaric tags for relative and absolute 
quantitation (iTRAQ) methodology, it was compared protein expression from non-transformed 
MDCK epithelial cells with protein profiles from Hakai-transformed MDCK cells, whereby the 
EMT program is induced. Some of the identified Hakai-regulated proteins using iTRAQ 
technique and validated independently by Western Blotting were Hsp90 and Hsp70, which are 
molecular chaperons. Molecular chaperones play essential roles in the folding of newly 
synthesized proteins and the refolding of denatured proteins (Bukau et al, 2006; Young et al, 
2004). 
 
 
2.1.2 Hsp90 and cancer 
Hsp90, a 90-kDa heat shock protein, is a molecular chaperone that facilitates the stabilization 
and activation of around 350 “client proteins” (Taipale et al, 2012), abundant in the cytosol and 
exert distinct functions in the protein folding pathway (Nollen et al, 2002; Wegele et al, 2004). 
Although Hsp90 assists in the productive folding of proteins, this chaperone appears to have 
more specialized functions in the folding/assembly pathways (Csermely et al, 1998; Pratt and 
Toft, 2003; Wegele et al, 2004). For instance, members of the cyclin dependent kinases family 
(e.g. Cdk4, Cdk6) are stabilized by Hsp90 before forming functional complexes and in their 
final enzymatic forms (Vaughan et al, 2006). Furthermore, many Hsp90 client proteins are 
known to be associated with cancer phenotypes. Akt, Src, Raf1, Bcr-Abl, and ErbB2 are Hsp90-
dependent protein kinases involved in signal transduction pathways required for abnormal 
cancer cell growth (Neckers et al, 2002). Hsp90 regulates the activity of the tumour suppressor 
protein p53 (Muller et al, 2004) and regulates the degradation of hypoxia-inducible factor 1, a 
transcription factor important for tumour cell survival under hypoxic conditions (Isaacs et al, 
2002). These observations indicate that Hsp90 plays crucial roles in cancer cell growth and 
survival by chaperoning tumorigenic proteins. It has been proposed that given that Hsp90 client 
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proteins include a number of oncogenic proteins, using specific inhibitors targeting Hsp90 
could be a promising anticancer strategy (Neckers et al, 2002). 
 Interestingly, Hsp90 is constitutively expressed at 2–10-fold higher levels in tumour 
cells than their normal counterparts (Ferrarini et al,1992), and it appears to be required for 
malignant transformation (Workman, 2007). Neoplastic cells frequently overexpress Hsp90, 
and a number of oncogenic signalling proteins depend on Hsp90 function, including ErbB2, 
Src family kinases, Akt, Raf-1, mutated p53, and HIF-1 (Neckers, 2002). Increased expression 
of Hsp90 has been reported in a range of solid tumours originating from the oesophagus, lung, 
breast, and pancreas (Shirota et al, 2015). Hsp90 is present in multiprotein complexes that are 
predominant in cancer cells but not in normal cells. The presence of these Hsp90 complexes in 
tumour cells is consistent with a major role for Hsp90 as the cancer chaperone-buffering and 
stabilizing metastable and potentially damaging mutant proteins during the evolution and 
progression of malignancy. This is consistent with the idea that Hsp90 is absolutely required 
for malignant progression (Workman, 2004). 
 
 
2.1.3 Hsp70 and cancer 
Hsp70 is a member of highly conserved Hsp70 family of molecular chaperones, which are 
found in every membranous organelle of all cells (Bukau et al, 2006). Unlike Hsp90, there are 
no truly specific ‘client’ proteins for Hsp70. Instead, this protein binds to stretches of exposed 
hydrophobic residues on unfolded and misfolded proteins, holding them in an intermediately 
folded state and preventing their aggregation. Furthermore, different to Hsp90, Hsp70 can 
directly unfold misfolded proteins, in an adenosine triphosphate (ATP)-dependent fashion 
(Murphy, 2013). The accumulated data on Hsp70 strongly argue that this chaperone can play a 
crucial role in cancer initiation. There are extensive evidences that Hsp70 is overexpressed in 
cancer, and that high expression of this chaperone correlates with increased tumour grade and 
poor prognosis. For instance, Hsp70 overexpression is a marker of early hepatocellular and 
prostate cancer (Chuma et al, 2003; Abe et al, 2004). 
 It is generally held that elevated Hsp70 expression in transformed cells protects these 
cells from apoptosis, from the stress associated with aneuploidy, accumulation of mutated 
protein and from the proteotoxic stress associated with abnormally rapid proliferation (Murphy, 
2013). Though Hsp70 is overexpressed in most human cancers, there are some tumour types 
were lower expression of Hsp70 is observed compared to adjusted normal tissues, and 
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correlation between and survival is lacking. Moreover, an inverse correlation between Hsp70 
expression and patient’s prognosis in observed in some cancers, such as squamous cell 
carcinoma, cholangiocarcinoma, oral, or lung cancer (Sherman et al, 2014). 
 
 
2.2 Colon cancer progression 
Colorectal cancer provides a good model for the study of morphological and genetic stages in 
cancer progression (Kinzler et al, 2002). Adenomatous polyp (or colon adenoma) represents a 
tumour of benign neoplastic epithelium with variable potential for malignancy and it is widely 
accepted that more than 95% of colorectal cancers arise from adenomatous polyps (Bujanda et 
al, 2010). A number of different staging criteria have been used to estimate the depth of cancer 
penetration in the colon as well as the extent of extra-colonic disease involvement. Nowadays, 
the most used staging method for colon cancer is based on the TNM (Tumour-Node-Metastasis) 
system as delineated by the American Joint Committee on Cancer (Compton et al, 2012). 
In colorectal cancer, in stage 0 (carcinoma in situ stage), abnormal cells are found in the mucosa 
(innermost layer) of the bowel wall, these abnormal cells may become cancer and spread. At 
stage I the cancer cells are growing in the colon or rectum walls, histologically denotes a well-
differentiated intestinal-type adenocarcinoma and well-formed glands with open lumina or with 
more than 95% glandular differentiation. It has not spread into nearby tissue or lymph nodes. 
In the stage II, cancer has grown through the wall of the colon or rectum, through the layers of 
the muscle to the lining of the abdomen, called the visceral peritoneum or through the wall of 
the colon or rectum and has grown into nearby structures. However, it has not spread to nearby 
tissue or to the nearby lymph nodes. Histologically adenocarcinoma is moderately 
differentiated intestinal-type with 50%-95% of glandular differentiation. At stage III cancer 
grows beyond the colon or rectum walls until to reach neighbouring tissues or lymph nodes. A 
poorly differentiated intestinal-type carcinoma can be seen through histologically analysis. 
Finally, in the stage IV cancer has spread to other parts of the body producing metastasis and it 
is seen an undifferentiated tumour which have less than 5% glandular differentiation (Bujanda 
et al, 2010). 
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     Figure 4. Schematic colon cancer staging. (Source: National Cancer Institute) 
 
 
 
 
 
2.3 Inflammation 
The malignant tumour microenvironment consists of tumour, immune, stromal, and 
inflammatory cells which produce cytokines, growth factors, and adhesion molecules that 
promote cancer progression and metastasis (Lewis et al, 2006). In 1863, for first time Virchow 
hypothesized that the origin of cancer was at sites of chronic inflammation, in part based on his 
hypothesis that some classes of irritants, together with the tissue injury and ensuing 
inflammation they cause, enhance cell proliferation (Balkwill et al, 2001). Several types of 
inflammation (differing by cause, mechanism, outcome, and intensity) can promote cancer 
development and progression, however, not all inflammatory response increase cancer risk 
(Grivennikov et al, 2010). Tumour-associated macrophages and their mediators affect key 
elements in the multistep process of invasion and metastasis, from interaction with the 
extracellular matrix to the construction of a premetastatic niche. Several evidences indicate that 
inflammatory mediators affect genetic stability and cause persistent epigenetic alterations 
suggesting that inflammatory components of the tumour microenvironment impacts on 
fundamental mechanisms responsible for the generation of metastatic variants (Mantovani et 
al, 2010). 
 It has been reported several cytokines and growth factors that are important in the 
tumour microenvironment to promote cancer progression such as IL-1β, TGFβ1, CD68, 
CD163, COL1A1, CCL5 and CCL20. For instance, IL-1β (Interleukin 1 beta) is a pleiotropic 
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cytokine with numerous roles in both physiological and pathological inflammatory states. It is 
known to be up regulated in many tumour types and it has been implicated as a factor in tumour 
progression via the expression of metastatic and angiogenic genes and growth factors (Lewis et 
al, 2006). On the other hand, in normal and premalignant cells, TGFβ1 (Transforming Growth 
Factor beta 1) enforces homeostasis and suppresses tumour progression directly through cell-
autonomous tumour-suppressive effects (cytostasis, differentiation, apoptosis) or indirectly 
through effects on the stroma (suppression of inflammation and stroma-derived mitogens). 
However, when cancer cells lose TGFβ1 tumour-suppressive responses, they can use TGFβ1 
to their advantage to initiate immune evasion, growth factor production, differentiation into an 
invasive phenotype, and metastatic dissemination or to establish and expand metastatic colonies 
(Massaguè, 2008). TNF (Tumor Necrosis Factor-α) also stimulates proliferation, survival, 
migration, and angiogenesis in most cancer cells that are resistant to TNF-induced cytotoxicity, 
resulting in tumour promotion.  CD68 (Clusters of Differentiation 68) is a glycoprotein, and 
CD163 (Clusters of Differentiation 163) is a member of the scavenger receptor family that 
functions as innate immune sensor for bacteria, both are monocyte/macrophage markers. 
Finally, COL1A1 (Collagen type I alpha 1) expression appeared to be associated with 
metastasis, furthermore it was recently found to be associated to a variety of tumour types, and 
the expression of COL1A1 was high in tumour tissues and cells (Tian et al, 2015). CCL5 and 
CCL20 are two pro-inflammatory chemokine (small signalling protein) and their main function 
consists in the activation and recruitment of the leucocytes in the sites of inflammation. 
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3. MATERIALS AND METHODS  
 
3.1 Immunohistochemistry 
Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded sections of 
tumours. Sections were stained for Hsp90 using a polymer-based method (Envision + Dual 
Link System-HRP; Dako). 
         Sections were deparaffinized in xylene and rehydrated through a graded ethanol series 
(100%–70%) and antigen retrieval was performed by heating in a Target Retrieval Solution, 
citrate pH 6 (Dako) in a pressure cooker at 121°C for 15 min. Endogenous peroxidase activity 
was blocked by incubation in 0.3% hydrogen peroxide solution (Dako) for 15 min and then 
washed with PBS/Tween-20 buffer (sodium chloride 0.15 M, potassium chloride 0.0027 M, 
Tween20 0.05%, sodium phosphate buffer 0.010 M). To minimize non-specific interactions of 
the antibody samples were blocked for 30 min at room temperature with 2% BSA and 1% TX-
100. Then the samples were incubated overnight at 4 °C in a wet chamber with the primary 
antibody diluted in Dako antibody diluent (Dako). As the negative control slides were only 
incubated with the antibody diluent, in absence of the primary antibody. After washing in 
PBS/Tween-20 buffer for three times, the sections were incubated with the peroxidase labelled 
polymer conjugated to goat anti-mouse immunoglobulins in Tris-HCl buffer for 1 hour at room 
temperature, then washed in PBS/Tween-20 buffer three times. The samples were incubated 
with the DAB+ substrate-chromogen buffer solution (DakoReal Envision kit) for 5 min then 
washed for three times with distilled water. Finally, the tissue sections were counterstained with 
Gill’s Hematoxylin, dehydratated through a graded ethanol series (70%–100%), then in xylol 
and mounted with DePeX (Serva). 
 Sixteen formalin-fixed and paraffin-embedded (FFPE) colon cancer tissues (4 μm) 
corresponding to the different stages of colon cancer progression (TNM I-IV, four per each 
stage), four adenomas and the corresponding adjacent normal colon tissues were used for 
immunochemistry with anti-Hsp90 antibody. Five pictures of each section were taken using an 
Olympus BX61 microscope and the images were quantified with ImageJ software (H-DAB 
settings). 
Colon cancer biopsies were obtained from the Pathological Anatomy department from the 
Complejo Hospitalario Universitario A Coruña (CHUAC), under informed consent from all 
patients signed and research investigation was approved by the Research Ethics Committee 
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from A Coruña-Ferrol. Paraffin samples were provided by CHUAC Biobank integrated in the 
Spanish Hospital Platform Biobanks Network. 
 
 
3.2 Antibodies 
For immunochemistry the mouse monoclonal anti-Hsp90 antibody (ab13495) and anti-Hsp70 
antibody (ab53496) were from Abcam. 
 For the western blot analysis the antibodies used, the mouse anti-GAPDH and rabbit 
anti-Hakai were obtained from Invitrogen™, anti-Hsp90 antibody was from Abcam. The 
secondary antibody used were Amersham ECL Mouse IgG HRP-linked whole antibody (from 
sheep) and Amersham ECL Rabbit IgG, HRP-linked whole antibody (from donkey), both from 
GE Healthcare Life Sciences. 
 Finally, for immunofluorescence analysis rabbit polyclonal anti-HSP90-α antibody 
(NB120-2928) from Novus Biologicals (Colorado, USA) and mouse monoclonal anti-GFP 
antibody [9F9.F9] (ab1218) from Abcam were used. The secondary antibodies were Labelled 
Donkey Anti-Rabbit IgG Antibodies from InvitrogenTM and Alexa Fluor® 488 Goat anti-mouse 
IgG from Abcam. 
 
 
3.3 Statistical analysis  
Immunohistochemistry quantification did not follow a normal distribution therefore was used 
Kruskal-Wallis with Tukey correction test. Significance of the Student t-test and Kruskal-
Wallis with Tukey correction test among the experimental groups indicated in the figure X is 
shown as * P<0.05 was made with GraphPad Prism software. 
 
 
3.4 Cell lines 
In this study, LoVo (ATCC® CCL-229™) cell line, colon rectal carcinoma cells derived from 
left supraclavicular region metastatic site, was used. Cell cultures were obtained from frozen 
cell lines in freezing medium containing 90% fetal bovine serum (-FBS-, from Life 
Technologies, USA) and 10% DMSO (Sigma-Aldrich, Germany), maintained in cryovials at -
196 ° C. 
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The LoVo line was cultivated in F12 medium (ThermoFisher, USA) supplemented with 10% 
FBS, 1% penicillin (100 U/Ml, Gibco) and streptomycin (100 µg/Ml, Gibco). 
LoVo cells were cultivated in 100 mm culture plates (Sigma-Aldrich, Germany) and the 
cultures were maintained at 37ºC in a 5% atmosphere in CO2 and 95% humidity, keeping passes 
each time they reached a confluence of between 80-90% of the total plate. Furthermore, 
Mycoplasma test was checked by PCR during culture routinely using Taq PCR kit (New 
England BioLabs, USA). 
 
 
3.5 Transfection 
LoVo cells were transfected with pcDNA-GFP-Hakai, using Lipofectamine® 2000 reagent 
(Invitrogen, USA), with a DNA (μg) to Lipofectamine 2000 (μl) ratio of 1:2, following the 
manufacturer instructions. 
 
 
3.6 Western blot 
3.6.1 Protein extraction from cells 
Medium was removed from the confluent cell culture and washed twice with PBS 1X pH 7.6 
(MPBiomedicals, USA). Cells of the plate were “scraped” using 1mL of PBS and cell 
suspension was collected in an Eppendorf tube, then centrifuged at 5000 rpm for 5 min at room 
temperature. The supernatant was discarded and the pellet was resuspended in 40μL of TritonX-
100 1X lysis buffer (20mM Tris-HCl pH 7.5, 150 mM NaCl and 1% of TritonX-100) 
supplemented with phenylmethylsulfonyl fluoride (PMSF) 1X and a mix of 1X protease 
inhibitors (Sigma-Aldrich, Germany). Protein extracts were incubated for 20 minutes at 4°C 
and then centrifuged at 12,000rpm for 10 minutes at 4°C in a refrigerated centrifuge 
(Microfuge® 22R Centrifuge, Beckman CoulterTM, USA). The supernatant obtained was 
recovered in a new Eppendorf tube and stored at -20°C. 
 
3.6.2 Protein quantification by BCA method and samples preparation 
To determine protein concentration of each sample the bicinchoninic acid assay (BCA 
assay), using PierceTM BCA protein assay kit (Thermo Scientific, USA) was used. 
BCA method is a colorimetric assay based on the reduction of Cu+2 to Cu+ in the presence of 
proteins, in a medium with high pH (alkaline). The Cu+ ions generated as a consequence of the 
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reduction of Cu+2 bind to the bicinchoninic acid, which acts as a chelant, and as a consequence 
a purple compound is formed. The union of the Cu+ ions to the BCA causes them to vary their 
electronic structure, being able to absorb light at 562 nm. Under the conditions of the reaction, 
the absorbance of the compound is proportional to the concentration of protein present. Proteins 
present in the solution were quantified by measuring the absorption spectra and comparing with 
BSA (bovine serum albumin) curve, on wich the concentration dilution is know. Nanoquant 
Infinite M200 (Tecan, Switzerland) was used to measure absorbance. 
            Twenty μg of protein from each samples were loaded and 2 μl of loading buffer 5X (4% 
SDS, 20% glycerol, 10% 2-mercaptoetanol, 0,004% bromophenol blue, 0.125 M Tris-HCl) was 
added. Finally, samples were incubated at 95° for 10 min (to denature proteins) in a 
thermoblock (Thermoleader, UniEquip, Germany) and stored at -20°C until its later use. 
 
3.6.3 Sodium Dodecyl Sulphate PolyAcrylamide Gel 
Electrophoresis (SDS-PAGE) 
The resolving gel was prepared at 10% acrylamide. As follow: Tris/HCl 1,5M (pH 8.8) (Trizma 
Base, Sigma-Aldrich, Germany), 10% glycerol (Sigma-Aldrich, USA), 10% acrylamide/bis-
acrylamide (NZYTech, Portugal), 0,1% SDS (Sigma-Aldrich, USA), 0,15% TEMED 
(NZYTech, Portugal) and 0,03% APS (Sigma-Aldrich, Germany).  
            The stacking gel was prepared at 4% acrylamide. As follow: Tris/HCl 0,5M (pH 6.8) 
(Trizma Base, Sigma-Aldrich, Germany), 40% acrylamide/ bis-acrylamide (NZYTech, 
Portugal), 0.1% SDS (Sigma-Aldrich, USA), 0.1% TEMED (NZYTech, Portugal) and 0.1% 
APS (Sigma-Aldrich, Germany). 
            The solutions were introduced in a vertical electrophoresis apparatus (CriterionTM 
Vertical Electrophoresis Cell, BioRad, USA) and the running condition used were 80V for 20 
minutes and 200V for 1 hour, at room temperature. Samples were loaded and the molecular 
weight marker used was NZYColour Protein Marker I (Nzytech, Portugal). 
 
3.6.4 Electroblotting 
To perform the electroblotting (protein transfer onto a membrane) PVDF (polyvinylidene 
difluoride) membrane (Millipore Immobion-P, USA) was used. Firstly, PVDF membrane was 
activated with methanol for 15 seconds and moistened in water. The assembly of the transfer 
was carried out following the instructions of the Criterion™ blotter (BioRad, USA). The device 
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is designed to perform the transfer in humidity and 1X transfer buffer (Trizma base 0.025 mM, 
glycine 0.192 M and 20% methanol in water) was used. The conditions of the transfer were: 
200mA for 1 hour, on ice. 
 
3.6.5 Immunodetection 
The membranes were incubated for 1 hour at room temperature in a blocking buffer: TBST 1X 
(10% Tris buffered saline 10X + 0.05% Tween 20 in water) + 5% Skim Milk Powder (Sigma-
Aldrich, Germany). After blocking, the membrane was incubated at 4°C overnight and in 
agitation with the primary antibody (to detect a specific protein), diluted in the blocking buffer. 
Antibody dilution used for primary antibody was 1/1000, except for GAPDH which was used 
at a dilution 1/10000. After incubation with the primary antibody, membranes were washed 
three times in TBST 1X for 10 minute in agitation. Then the membrane was incubated at room 
temperature for 1 hour with the secondary specific antibody diluted in blocking buffer (1/2000 
dilution). The secondary antibodies are conjugated with horseradish peroxidase (HRP), which 
allows its subsequent detection by a chemiluminescence reaction. Finally, by adding Amersham 
ECLTM Western Blotting Analysis System (GE Healthcare Life Sciences, UK), a specific 
compound which increases the intensity of the light emitted in the chemiluminescence, the 
protein was detected in the Amersham Imager 600 (GE Healthcare Life Sciences, UK). 
 
 
3.7 Immunofluorescence 
For the immunofluorescence, LoVo cells were seeded on sterile glass coverslips previously 
placed on wells (Corning® CellBIND® Multiple Well Plate). After 24 hours of incubation at 37 
° C, in an atmosphere of 5% CO2 and 95% humidity, the cells were washed twice with PBS 
(1x PBS 0.1% Tween 20 pH 7.4), and then fixed in a 4% solution of paraformaldehyde (PFA) 
in PBS for 15 minutes at room temperature. After fixation, the PFA was removed and washed 
with PBS three times, and then cells were permeabilized using Triton X-100 / 0.25% PBS for 
15 minutes at room temperature, to allow the access of the antibody into the cell. Once removed 
the Triton X-100 / 0.25% PBS, the cells were blocked incubating with F12/10% FBS for 1 hour, 
to reduce unspecific binding of the antibodies. Then, the samples were incubated for 2 hours at 
room temperature with the primary antibody (GFP-antibody, 1:500 dilution; Hsp90-antibody, 
1:200 dilution), diluted in block buffer (F12/10% FBS). After washing with PBS twice, the 
cells were incubated for 1 hour at room temperature and in the dark with the specific secondary 
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antibody, diluted in block buffer (F12/10% FBS). The samples were washed 3 times with PBS, 
then incubated for 5 min, in the dark, at room temperature with the Hoechst 33342 (Life 
Technologies, USA) in PBS (1/2000 dilution) to stain the nuclei. After washing with PBS, a 
final wash with distilled water was performed to remove excess of salts. Finally, the crystals 
were mounted on clean, pre-labelled slides using ProLong® Gold Antifade Mountant (Thermo 
Fisher Scientific, USA) and store in the dark at 4°C. 
The immunofluorescence visualization was performed by Motorized reflected Fluorescence 
System (Olympus, Japan). 
 
 
 
 
3.8 RNA extraction from formalin-fixed and paraffin-embedded (FFPE) tissues 
and qRT-PCR 
 
3.8.1 Deparaffinization of FFPE tissue and total RNA purification 
For inflammatory mRNA levels study, sections of formalin-fixed and paraffin-embedded 
tissues (4 μm) obtained from xenografts previously injected subcutaneously into the flank with 
five million MDCK cells or Hakai transformed MDCK cells were used.  
 In order to remove paraffin, FFPE tissue sections were put in a 1,5mL microcentrifuge 
tube, on which 1mL of 100% xylene was added. After vortexing and centrifuging (13,400 
rpm/min for 2 min), xylene was removed and added 1mL of ethanol (96-100%) to the pellet, 
and again vortexing and centrifuging (13,400 rpm/min for 2 min). Ethanol was removed and 
the precipitate tissues were were dry up at room temperature for 10 min (to remove any residue 
of ethanol). Samples were resuspended into 240μl of Buffer PKD (proteinase K digest buffer, 
QIAGEN) and 10μl of proteinase K, mixed by vortexed. Samples were incubated at 56° for 15 
min, then at 80° for 15 min.  
 For total RNA purification, samples were incubated on ice for 3 min, centrifuged for 15 
min at 13,400 rpm/min, and the supernatants were transferred to a new microcentrifuge tube. 
Samples were incubated with 25μl of DNase Booster Buffer (QIAGEN) and 10μl of DNase I 
for 15 min at room temperature, and then 500μl of RBC Lysis Solution (QIAGEN) and 1200μl 
of ethanol (100%) were added and mixed by pipetting. The samples were transferred to RNeasy 
MinElute spin column (QIAGEN) and centrifugated for 15 sec at 10,000 rpm/min. Two 
washing steps were performed adding 500μl of Buffer RPE to the RNeasy Min Elute spin 
column, and centrifuged for 15 sec and 2 min, respectively. The RNeasy Min Elute spin column 
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were centrifuged at 13,400 rpm/min for 5 min to eliminate the residual ethanol. Finally, the 
RNA was eluted by add 30μl RNase-free water directly to the spin column following by 
centrifugation at 13,400 rpm/min for 1 min. 
 
 
3.8.2 Nucleic acid quantification 
NanoDrop 1000 Spectrophotometer (Termo Fisher Scientifc, MA, USA) was used to determine 
the quantity and quality of RNA samples. 
 
3.8.3 Real-time quantitative PCR (qRT-PCR) 
Total RNA extracted was analysed by rea-time quantitative PCR (qRT-PCR). The first strand 
cDNA synthesis was performed using NZY First-Strand cDNA Synthesis Kit (NZYTech). 
Different amounts of total RNA were added to reach the quantity of 300ng for sample. Then, 
DEPC-treated water was added up to 20μl total. Samples were mixed and incubate at 25°C for 
10 min and next at 50° for 30 min. In order to inactivate the reaction by heating, samples were 
incubated at 85° for 5 min, and then chilled on ice. Finally, was added 1μl of NZY RNase H 
(E. coli) and incubate at 37°C for 20 min. 
            cDNA amplification was performed in a Light Cycler 480 II using following master 
mix: 5μl of LightCycler 480 SYBR Green I Master, 0,7μl forward primer, 0,7μl reverse primer, 
2,6μl of distilled water, 1μl of cDNA. Data was analysed by using the comparative CT method 
(Lightcycler400 software). For primers designing, a Primer3 Input (version 0.4.0) software was 
used. (Primer Sequences are indicated in table 1). 
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Table 1. Primers sequences used for inflammatory mRNA analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mRNA of interest Forward sequence Reverse sequence 
GAPDH 5’-GTGCTGAGTATGTCGTGGAGTCTAC-3’ 5’-GGCGGAGATGATGACCCTTTTGG-3’ 
RN18S 5’-CGATGCGGCGGCGTTATTC-3’ 5’-ATCTGTCAATCCTGTCCGTGTCC-3’ 
CD163 5’-CCTCCTCATTGTCTTCCTCCTGTG-3’ 5’-CATCCGCCTTTGAATCCATCTCTTG-3’ 
CD68 5’-TCCAAGATCCTCCACTGTTG-3’ 5’-ATTTGAATTTGGGCTTGGAG-3’ 
TNF-α 5’-ATGAGAAGTTCCCAAATGGC-3’ 5’-CTCCACTTGGTGGTTTGCTA-3’ 
TGF-β1 5’-CCCTATATTTGGAGCCTGGA-3’ 5’-CTTGCGACCCACGTAGTAGA-3’ 
IL-6 5’-CTCTGGGAAATCGTGGAAAT-3’ 5’-CCAGTTTGGTAGCATCCATC-3’ 
IL-1β 5’-CACAGCAGCACATCAACAAG-3’ 5’-GTGCTCATGTCCTCATCCTG-3’ 
CCL5 5’-AGATCTCTGCAGCTGCCCTCA-3’ 5’-GGAGCACTTGCTGCTGGTGTAG-3’ 
COL1A1 5’-GCTGAGATGGCAACAGGGCTA-3’ 5’-TTGATGGACGGGAATGAACA-3’ 
CCL20 5’-CGACTGTTGCCTCTCGTACA-3’ 5’-GAGGAGGTTCACAGCCCTTT-3’ 
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4. RESEARCH OBJECTIVES 
The main research objectives established for this work are the following: 
 
1. To evaluate the expression of heat shock protein 90 and heat shock protein 70 in healthy 
tissues, adenoma and different tumour stages. 
 
2. To determine whether the Hsp90 protein levels is regulated by the E3 ubiquitin-ligase 
Hakai overexpression in LoVo cells by western-blotting. 
 
3. To determine whether the Hsp90 protein levels are regulated by the E3 ubiquitin-ligase 
Hakai overexpression in LoVo cells by immunofluorescence.  
 
 
 
4.1 Secondary objective 
1. To analyse the mRNA levels of some specific inflammatory factors in sections of 
formalin-fixed and paraffin-embedded tissues obtained from xenografts injected 
subcutaneously with non-transformed MDCK cells or Hakai transformed MDCK 
cells. 
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5. RESULTS 
 
5.1 Analysis of Hsp90 protein expression in different colon cancer TNM stages by 
immunohistochemistry  
The Dra. Figueroa research group, in which I have been doing the TFM internship, has been 
working for years on the study of colorectal cancer and in particular focusing on role that E3-
ubiquitin ligase Hakai in the development of cancer. Our group has recently published a 
proteomic analysis comparing the protein expression in Hakai overexpressing normal epithelial 
MDCK cells at compared to normal MDCK cells (Figueroa et al, 2017). Among the found 
differentially expressed proteins, one of the most up-regulated proteins was Heat shock protein 
70 and Heat shock protein 90 (Hsp70) (Hsp90). The expression of Hsp90 has been reported in 
various types of cancer. 
 In order to analyse whether Hsp90 is differentially expressed in different colon cancer 
stages, we performed an immunohistochemistry. A total of 30 human colon samples were 
analysed including: different TNM stages (I-IV) from colon adenocarcinomas, colon adenoma 
compared to human colon healthy tissues (figure 5). In particular, adenoma and healthy colon 
tissues appear to present low levels of Hsp90 expression (figure 5a and 5b, respectively). On 
the contrary, the tissues belonging to different tumour stages (I-IV) present higher expression 
(black arrows in figure 5 c-f). 
Figure 5. Immunohistochemical analysis of Hsp90 protein expression in human 
samples from colon cancer patients. (a) Normal healthy colon tissue (b) adenoma (c) 
colon cancer stages I, (d) colon cancer stages II (e) colon cancer stages III and (f) colon 
cancer stages IV. Non-staining connective tissue (blue arrows) denotes the specificity of 
immunoreaction. Olympus BX61 microscope (Magnification of 200X). 
f 
e 
b 
a 
d 
c 
100 pixe l 
100 pixe l 
100 pixe l 
100 pixe l 
100 pixe l 
100 pixe l 
 26 
Implication of Hakai-regulated proteins in cancer 
 
 The fact that the brown colour is not present on the cells belonging to the connective 
tissue on the side of the tumour area indicated the specificity staining in epithelial colon tissue 
(blue arrows in figure 5: c-d-e-f). In order to determine whether the different expression levels 
observed between samples were statistically significant, quantification of the signal intensity of 
Hsp90 in the immunohistochemistry staining was performed using ImageJ software (figure 6). 
As seen in figure 6, an increase Hsp90 protein expression was detected from carcinoma 
compared to healthy and in the adenoma stage tissues. Moreover, it is important to note that no 
differences were detected between different TNM-stages (I-IV).  
 
 
 
 
 
 
 
 
Figure 6. Immunohistochemical quantification of Hsp90. Five pictures of each section 
(four different patient collections for every healty/tumor grade tissue) were taken with an 
Olympus BX61 microscope and the images were quantified with Image J software (H-DAB 
settings) (*P<0.05). 
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5.2 Immunohistochemistry of Hsp70 in different tumour stages 
Next, we decided to investigate the protein expression of another member of the Heat Shock 
Protein, the Hsp70. Once again, I have analysed different human tissue samples using biopsies 
corresponding to adenoma, TNM-stages from adenocarcinoma compared to adjacent colon 
healthy tissue. The images staining show that there are no differences between protein level of 
expression pf Hsp70 by comparing healthy tissue with adenoma and different stages of cancer 
from 1 to 4 (figure 7) 
Figure 7. Immunohistochemical analysis of Hsp70 protein expression in human samples 
from colon cancer patients. (a) Normal healthy colon tissue (b) adenoma (c) colon cancer stages 
I, (d) colon cancer stages II (e) colon cancer stages III and (f) colon cancer stages IV. Olympus 
BX61 microscope (Magnification of 200X). 
 
 
5.3 Western blotting analysis of Hsp90 in Hakai-transfected LoVo cells 
Given the interesting results obtained in the differential expression of Hsp90 protein expression 
in human colon adenocarcinoma, we decided to determine, the possible mechanism of action 
of Hakai on Hsp90 protein. For this purpose, we decided to transfect GFP-Hakai in LoVo colon 
cancer epithelial cells. Once we confirmed by western blot analysis that the overexpression of 
Hakai was detected (figure 8), I analysed the effect of Hsp90 protein expression to determine 
whether the protein regulation had occurred. As shown in figure 8, Hakai shows two different 
bands and molecular weights in correlation with endogenous Hakai (figure 8, lower band) and 
the correctly transfected GFP-Hakai (figure 8, upper band). However, no difference was 
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detected in Hsp90 protein levels in presence or absence of Hakai overexpression in LoVo 
transiently transfected cells, using GAPDH as loading control.  
 
 
Figure 8. Western blot of Hakai-transfected LoVo cells. LoVo cell 
lysate (Lane 1) and GFP-Hakai-transfected LoVo cell lysate (lane 2). 
GFP-Hakai band is only visible in the transfected LoVo cells (lane 2). No 
difference is detected in Hsp90 bands comparing normal LoVo cell lysate 
with Hakai-transfected LoVo cell lysate (lane 1 and 2, respectively).  
 
 
 
5.4 Immunofluorescence analysis of Hsp90 in Hakai-transfected LoVo cells 
Since the low transfection efficiency with the GFP-Hakai vector could affect the result seen in 
the western blotting, I evaluated whether the negative western blot result was due to a low 
population of transfected cells. For this purpose, I performed an immunofluorescence staining 
on GFP-Hakai plasmid transfected LoVo cells, using as negative control an empty GFP 
plasmid. As seen in figure 9, an increase in Hsp90 expression in correctly GFP-Hakai plasmid 
transfected cells (figure 9, orange arrow). On the contrary, the negative control, containing the 
GFP plasmid, does not show the same increase in fluorescence (figure 9, white arrows). 
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Figure 9. Effect of GFP-Hakai overexpression on Hsp90 in LoVo cells by 
immunofluorescence. GFP-Hakai (left panel) and GFP empty plasmid (right panel) 
transfected in LoVo cells. GFP-Hakai transfected cells (yellow arrow) show an increased 
fluorescence of Hsp90. Olympus BX61 microscope (total magnification of 200X). 
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5.5 Comparative study of inflammatory mRNA levels from xenografts injected 
subcutaneously with non-transformed MDCK cells or Hakai transformed 
MDCK cells 
In the recently published proteomic analysis mentioned, while comparing the protein 
expression in Hakai overexpressing normal epithelial MDCK cells and to normal MDCK cells 
(Diaz-Diaz et al, 2017), we have also found an important number of proteins involved in 
inflammation process.  Therefore, we decided to also analysed, as secondary objective in this 
project, whether we could find differences in inflammatory mRNA levels in vivo. For this 
purpose, we used an established mouse model in our lab, using tissue samples obtained from 
xenografts injected subcutaneously with non-transformed MDCK cells or Hakai transformed 
MDCK cells. As previously reported, non-transformed MDCK cells injected in 
immunocompetent mice formed teratomas while injected Hakai transformed MDCK cells 
formed aggressive tumours (Castosa et al, 2018). By using teratoma and tumours from these 
mice model, we analysed by qRTPCR the expression levels of different inflammatory mRNAs.  
The results obtained from the study of the different inflammatory mRNAs indicate that the 
"teratoma" samples (obtained from teratoma tissues formed in MDCK-injected mice) present a 
level mRNA expression higher than the "tumour" samples (obtained from tumour tissues 
formed in Hakai-MDCK-injected mice) in all different inflammatory mRNA that I analysed. 
Indeed, comparing mRNA levels between tumour and teratoma samples, it was found that 
CD163 shows a level of 25-fold change expression in teratoma compared to tumours (figure 
10, a). CD68 shows 10-fold expression higher in teratoma compared to tumours (figure 10, b), 
CCL20 and about 5-fold change in teratoma (figure 10, c). Interestingly, TGF-β, COL1A1, and 
CCL5 show a mRNA level higher in teratoma compared to cancer, around six thousand, forty 
thousand, and seventy thousand fold increase respectively (figure 10, d-e-f). Finally, IL-β and 
TNF-α show low expression levels in teratoma samples and it is almost absent in the 
carcinogenic samples (figure 10, g-h). All these results are not conclusive and further replicates 
in xenograft mouse model are necessary in order to conclude whether a differential expression 
of the inflammatory mRNA are regulated under Hakai influence. 
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Figure 10. Inflammatory mRNAs of xenografts injected subcutaneously with non-
transformed MDCK cells or Hakai transformed MDCK cells. Mean values of (a) CD163, 
(b) CD68, (c) CCL20, (d) TGF-β, (e) COL1A1, (f) CCL5, (g) IL-β, (h) TNF-α inflammatory 
mRNAs in tumour and teratoma tissues. 
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6.  DISCUSSION 
In a previous study of the Epithelial Plasticity and Metastasis Group, it has been shown that 
Hakai expression is gradually increased in adenoma and in different TNM stages (I-IV) from 
colon adenocarcinomas compared to human colon healthy tissues (Castosa et al, 2018). 
Moreover, in MDCK cells that stably overexpressed Hakai, it was detected an increase 
expression of the Hsp90 and Hsp70 proteins compared to normal, non-transformed MDCK 
(Diaz-Diaz et al, 2017). Given these premises, the differential expression during carcinoma 
progression in human colon adenocarcinoma was studies for Hsp70 and hsp90.  
 Collectively the immunohistochemical Hsp90 images (figure 5) show that the tissues 
belonging to the various tumour stages (I-IV) present an increased protein expression compared 
to healthy or adenoma tissues. An important change of expression level between the benign 
tumour (adenoma) and the malignant cancerous tumour occurs, as demonstrated by the 
subsequent quantification of the staining through the software ImageJ (figure 6). However, it 
does not seem to be statistical differences between Hsp90 protein levels between the different 
the different TNM-stages, further suggesting that Hsp90 is a relevant protein for the transition 
from adenoma to carcinoma. Unlike Hsp90, immunohistochemical staining of the Hsp70 
(figure 7) did not show any statistical differences in human colon adenocarcinoma during 
tumour progression. Indeed, no changes were detected while comparing healthy tissue with 
adenoma and different stages of cancer (I-IV). 
 The apparently increase expression levels of Hsp90 during human colorectal cancer 
progression may suggest that the existing stress factor such as hypoxia and acidosis at the 
beginning of colorectal cancer formation contribute to the higher Hsp90 expression level in 
colorectal cancer tissues compared to normal tissues (Qiu et al, 2014). Therefore, it would be 
interesting to determine whether Hakai and Hsp90 could act together in response to these factors 
and its impact at early stages tumour progression. Hsp protein family, specially Hsp90 protein, 
could play a role as “cancer chaperone” to promote cancer development. For instance, cancer 
cells could rely on the Hsp90 chaperone to protect a set of mutated and overexpressed client 
oncoproteins from misfolding and degradation (Neckers et al, 2012). Thus, Hsp90 could be a 
critical facilitator of “oncogene addiction” and cancer cell survival by its action on Hakai 
proteins; opening the possibility to study whether there is a mutual relationship between Hakai 
and Hsp proteins during cancer development. 
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A classical tumour marker for gastrointestinal cancers and CRCs is CEA (carcinoembryonic 
Antigen). CEA marker was discovered almost 50 years ago, in 1965, and it remains the only 
tumour marker of recognised efficacy in monitoring CRC patients therapy. However, the 
sensitivity and specificity of CEA for specific tumours is not precise since this protein is 
expressed widely in gastrointestinal mucosa. In a recent study, it was explored the diagnostic 
value of the new marker, Hsp90. Authors analysed the combination of tumour markers such as 
Hsp90 and CEA or CA 19-9 to show the potential diagnostic value of CRC at an early stage 
and monitoring the plasma Hsp90 pre- and post-surgery (Kasanga et al, 2018). They 
demonstrated that plasma Hsp90 was a powerful marker with better sensitivity and specificity 
than CEA and CA 19-9 in discriminating the early stage (I and II) father supporting our results 
obtained by immunohistochemistry on which Hsp90 was crucial at early stages of tumour 
progression. 
 On the other hand, as previously reported the Hsp70 protein plays a cryptic role within 
the cancer and it is proposed to have a pro-oncogenic or anti-oncogenic role depending on the 
type of cancer and genetic background. For instance, in cancer where the inflammatory 
component seems to be critical for its development, a decrease rather than increase in the levels 
of Hsp70 would promote cancer. Moreover, in cancer accompanied by a strong inflammation 
knockout of Hsp70 increased inflammatory cytokines and aggravated cancer (Sherman et al, 
2016). Although our results do not show any differential expression during human colon cancer 
progression, it would be interesting to determine whether this protein could be a biomarker in 
CCR associated to inflammation. Moreover, many authors reported that elevated levels of 
Hsp70 are critical to cancer cells to combat harsh conditions and suppress apoptosis. These 
early studies demonstrated that, surprisingly, besides its molecular chaperone function, Hsp70 
also plays a special role in apoptotic signal transduction (Rérole et al, 2011). Nowadays, Hsp70 
and Hsp90 play a crucial role in cancer but their molecular mechanism is still unknown. 
 Given the promising results, I further investigated whether Hsp90 protein is regulated 
in LoVo by transiently overexpressing the E3 ubiquitin-ligase Hakai protein by western blot 
and immunofluorescence analysis. The hypothesis that the Hsp90 protein could be over-
expressed in LoVo cells by transiently transfection of Hakai plasmid did not give positive 
results (figure 8), therefore, we speculate that it could be due to a low transfection efficiency. 
Next, I performed an immunofluorescence to detect Hsp90 in presence or absence of Hakai 
overexpression. In fact, from this experiment it has emerged that there is an increase expression 
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of Hsp90 in several Hakai-transfected cells (figure 9), suggesting that it could be a relationship 
between action of Hsp90 and Hakai, however this hypothesis should be deepen investigated. 
Overexpression and knockdown of Hakai seems to affects cell proliferation in some cell lines, 
thus, it is plausible that Hakai interacting with other proteins than E-cadherin (Figueroa et al, 
2009). Several publications reported alterations in the regulation of Hsp in many types of cancer 
and recent studies are investigating the role of Hsp90 localizing at the membrane level and in 
the extracellular environment, which is still unknown.  
 HSP is a group of highly conserved proteins synthesized after heat induction. During 
the growth and development of normal cells, Hsp70 and Hsp90 are constitutively expressed at 
low or moderately levels, but the expression is dramatically enhanced by stressful condition 
(Hosseinzadeh et al, 2012). Heat shock proteins can act promoting cancer survival also in a 
condition of intracellular proteotoxic stress. Intracellular environment is incredibly chaotic 
(crowding phenomenon) even more in a cancerous cell, on which the protein regulation is lost 
and some genes are continually expressed. Then, it may be possible to find a correlation 
between the levels of heat shock protein present in tumour tissue and different cancer staging, 
such Hsp90 in colorectal and liver cancer (Kasanga et al, 2018; Sourbier, 2017). 
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7. CONCLUSIONS 
 
1. The Hsp90 levels increase from the transition from healthy and adenoma tissues to 
carcinoma in human colon adenocarcinoma progression. 
 
2. No significant differences in protein levels of Hsp70 expression were detected by 
comparing healthy tissue, adenoma and different stages of human colon 
adenocarcinoma (I-IV). 
 
3. It was not detect differences in expression of Hsp90 protein levels in presence or 
absence of Hakai overexpression in LoVo transiently transfected cells, by western-
blotting. 
 
4. By immunofluorescence analysis, it was detected an increase expression of Hsp90 
protein levels in presence of Hakai overexpression in LoVo cells by transiently 
transfection. 
 
5. Comparative study of inflammatory mRNA levels in xenograft mouse model injected 
subcutaneously with non-transformed MDCK cells or Hakai-transformed MDCK cells 
is not conclusive. Further experiments are necessary in order to determine whether the 
inflammatory mRNA expression is regulated under Hakai influence. 
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